English, Article edition: Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation: Comparing Valaciclovir Prophylaxis with Current Practice Josephine A. Mauskopf; Anke Richter; Lieven Annemans; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118891
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation: Comparing Valaciclovir Prophylaxis with Current Practice
Author
  • Josephine A. Mauskopf
  • Anke Richter
  • Lieven Annemans
  • Grant Maclaine
Physical Description
  • article
Notes
  • Background: Cytomegalovirus (CMV) disease may occur following renal transplantation and has been shown to have health and cost consequences in this setting. Objective: To compare the cost effectiveness of different CMV management strategies for renal transplant patients: prophylaxis with (i) oral valaciclovir or (ii) intravenous ganciclovir; viral testing for CMV followed by (iii) pre-emptive therapy with intravenous ganciclovir or (iv) adjustment of immunosuppression and intensive monitoring; or (v) waiting to treat when CMV disease develops. Methods: A decision-tree model was constructed that included the different management strategies for the donor seropositive/​recipient seronegative (D+R-) population. Clinical outcomes for the D+R- population came from clinical trials. Treatment algorithms and costs for CMV syndrome and tissue invasive disease were developed from published literature and UK physician interviews. One- and 2-way sensitivity analyses were performed. Study Perspective: UK National Health Service. Results: Prophylaxis with either oral valaciclovir or intravenous ganciclovir dominated (lower costs and fewer cases of CMV disease) the pre-emptive treatment and wait-and-treat strategies. The cost per patient was from Lstg 157 to Lstg 438 higher with oral valaciclovir prophylaxis compared with intravenous ganciclovir prophylaxis and the incremental cost per case of CMV disease avoided with valaciclovir prophylaxis ranged from Lstg 2243 to Lstg 8111 (1996 values). These results are sensitive to the efficacy of intravenous ganciclovir prophylaxis and CMV management costs. Conclusions: For D+R- renal transplant patients, prophylaxis is the dominant (more effective and less costly) management strategy compared with pre-emptive and wait-and-treat strategies. The cost per patient with oral valaciclovir prophylaxis compared with intravenous ganciclovir prophylaxis is slightly higher in our base case scenario, but may be lower under reasonable alternative assumptions.
  • Antivirals, Cost effectiveness, Cytomegalovirus infections, Ganciclovir, Nucleosides, Pharmacoeconomics, Valaciclovir
  • RePEc:wkh:phecon:v:18:y:2000:i:3:p:239-251
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment